In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells.
Front Immunol. 2018 Nov 5;9:2552. doi: 10.3389/fimmu.2018.02552. eCollection 2018.
Front Immunol. 2018.
PMID: 30455699
Free PMC article.